Vaxcyte, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vaxcyte, Inc. (PCVX) on May 1, 2025. The report discloses the appointment of a new member to the Board of Directors and details the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on corporate governance and director compensation.
Material Changes
On May 1, 2025, the Board of Directors appointed Dr. Olivier Brandicourt as a Class III director, effective immediately. His term will expire at the 2026 annual meeting of stockholders. The Board determined Dr. Brandicourt qualifies as an independent director under Nasdaq Rules.
Compensatory Arrangements and Outlook
In connection with his appointment, Dr. Brandicourt will receive the following compensation under the Company's Director Compensation Program:
- Initial Equity Award: A nonstatutory stock option with an equivalent value of $800,000. Vesting occurs over 36 months (1/3 on the first anniversary, with the remainder vesting monthly).
- Annual Equity Grant: An award with an equivalent value of $450,000 granted at each annual meeting. This consists of 75% nonstatutory stock options and 25% restricted stock units (RSUs). Both components vest fully on the earlier of the first anniversary of the grant date or the day prior to the next annual meeting.
- Cash Retainer: An annual cash retainer of $50,000, pro-rated for partial periods of service.
- Change in Control: The Annual Grant becomes fully vested upon a change in control, subject to continuous service.
The Company has also entered into a standard indemnification agreement with Dr. Brandicourt.
Investor Verification Checklist
- Verify the total number of shares underlying the $800,000 initial option grant based on the grant date stock price.
- Confirm the impact of the new director appointment on the Board's independence status and committee assignments.
- Review the Company's 2020 Equity Incentive Plan to ensure sufficient shares remain available for these grants.
- Monitor future filings for the actual grant date and exercise price of the initial and annual equity awards.